Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct 31:12:7993-8007.
doi: 10.2147/IJN.S146927. eCollection 2017.

Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening

Affiliations
Review

Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening

Marie Millard et al. Int J Nanomedicine. .

Abstract

The increasing number of publications on the subject shows that nanomedicine is an attractive field for investigations aiming to considerably improve anticancer chemotherapy. Based on selective tumor targeting while sparing healthy tissue, carrier-mediated drug delivery has been expected to provide significant benefits to patients. However, despite reduced systemic toxicity, most nanodrugs approved for clinical use have been less effective than previously anticipated. The gap between experimental results and clinical outcomes demonstrates the necessity to perform comprehensive drug screening by using powerful preclinical models. In this context, in vitro three-dimensional models can provide key information on drug behavior inside the tumor tissue. The multicellular tumor spheroid (MCTS) model closely mimics a small avascular tumor with the presence of proliferative cells surrounding quiescent cells and a necrotic core. Oxygen, pH and nutrient gradients are similar to those of solid tumor. Furthermore, extracellular matrix (ECM) components and stromal cells can be embedded in the most sophisticated spheroid design. All these elements together with the physicochemical properties of nanoparticles (NPs) play a key role in drug transport, and therefore, the MCTS model is appropriate to assess the ability of NP to penetrate the tumor tissue. This review presents recent developments in MCTS models for a better comprehension of the interactions between NPs and tumor components that affect tumor drug delivery. MCTS is particularly suitable for the high-throughput screening of new nanodrugs.

Keywords: accumulation; cytotoxicity; distribution; nanodrug; tridimensional model.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Schematic representation of NP EPR effect in tumor tissue. Note: Tumor tissues show a disorganized vascular network with fenestrated blood vessels involving an improvement in NP extravasation and a lack of lymphatic vessels compared to normal tissues. Abbreviations: ECM, extracellular matrix; EPR, enhanced permeability and retention; NP, nanoparticle.
Figure 2
Figure 2
Schematic representation of similarity between tumor and MCTS. Notes: MCTS (left panel) displays similarities with in vivo tumor (right panel). MCTS is composed of proliferative cells in periphery, quiescent cells in the intermediate zone and a necrotic core. Three concentration gradients (nutrients, pH and oxygen) are comparable to the situation in avascular tumor regions. Abbreviations: ECM, extracellular matrix; MCTS, multicellular tumor spheroid; NP, nanoparticle.
Figure 3
Figure 3
NP properties affecting drug penetration in MCTS. Abbreviations: MCTS, multicellular tumor spheroid; NP, nanoparticle; PEG, polyethylene glycol.
Figure 4
Figure 4
Number of publications by year. Note: In all, 160 publications were found on the subject of NPs and MCTS. Abbreviations: MCTS, multicellular tumor spheroid; NP, nanoparticle.

Similar articles

Cited by

References

    1. Zamboni W, Torchilin V, Patri A, et al. Best practices in cancer nanotechnology: perspectives from NCI nanotechnology alliance. Clin Cancer Res. 2012;18(12):3229–3241. - PMC - PubMed
    1. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm. 2011;8(6):2101–2141. - PubMed
    1. Wicki A, Witzigmann D, Balasubramanian V, Huwyler J. Nanomedecine in cancer therapy: challenges, opportunities and clinical applications. J Control Release. 2015;200:138–157. - PubMed
    1. Marchal S, Hor AE, Millard M, Gillon V, Bezdetnaya L. Anticancer drug delivery: an update on clinically applied nanotherapeutics. Drugs. 2015;75(14):1601–1611. - PubMed
    1. Netti P, Berk D, Swartz M, Grodzinsky A, Jain R. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res. 2000;60(9):2497–2503. - PubMed

MeSH terms

LinkOut - more resources